Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021. Although the request identifies Alaunos Therapeutics, the filing names ZIOPHARM Oncology, Inc. as the registrant (Nasdaq: ZIOP). The company was a clinical-stage immuno-oncology developer with no recurring operating revenue, focused on its Sleeping Beauty cell-therapy platform and Controlled IL-12 program.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | No significant revenue; no product sales | No significant revenue |
| Research and development expense | $13.3 million | $12.7 million; up 5% |
| General and administrative expense | $8.2 million | $6.0 million; up 38% |
| Total operating expenses | $21.6 million | $18.7 million |
| Net loss | $21.6 million; $0.10 per share | $18.3 million; $0.09 per share |
| Cash used in operating activities | $15.3 million | $9.9 million |
| Cash and cash equivalents | $100.1 million at March 31 | $115.1 million at December 31, 2020 |
| Working capital | $93.7 million | $112.2 million at December 31, 2020 |
No operating margin is meaningful because the company had no significant revenue. The filing reports no conventional borrowings; reported liabilities include lease obligations. Total liabilities were $22.8 million, including $4.6 million of current and noncurrent lease liabilities. Contractual obligations were reported at $11.9 million, including operating leases, CRADA commitments, royalty and license fees, and strategic advisory fees.
Material changes versus the prior comparable period
- Net loss increased $3.3 million year over year. Higher R&D expense reflected increased headcount, stock compensation, facilities and cell-therapy costs, partly offset by lower Controlled IL-12 costs.
- G&A expense rose $2.3 million, including costs related to the former CEO’s separation, employee expenses, patent portfolio expansion and advisory fees.
- Operating cash use increased $5.4 million. Q1 2020 financing included $88.7 million of net public-offering proceeds and $13.0 million from the ATM program; Q1 2021 had no ATM or offering proceeds.
Outlook, commentary, risks and unusual items
- Management estimated that cash resources would fund operations into the second quarter of 2022, based on current development plans. The company had no committed additional financing and warned that it would need substantial additional capital; failure to obtain funding could delay or reduce programs.
- After quarter-end, on May 6, 2021, the company announced plans to wind down Controlled IL-12 clinical trials and shift resources toward Sleeping Beauty TCR. It expected to reduce its workforce by approximately 15%; estimated severance and termination-related costs were approximately $0.8 million, expected to be recorded in Q2. The company was also assessing facilities, vendors and related wind-down obligations.
- The company reported FDA clearance in February 2021 for its company-sponsored Phase 1/2 library TCR trial. In April, it announced the first patient infusion in Eden BioCell’s CD19 RPM CAR-T trial in Taiwan. The NCI-sponsored personalized TCR trial had temporarily suspended enrollment for reasons internal to the NCI.
- Leadership changed during the quarter: Heidi Hagen became interim CEO and Timothy Cunningham interim CFO. The filing also reports a $0.6 million Q1 charge related to former CEO Laurence Cooper’s separation; additional separation and consulting costs were expected.
- Key risks include clinical and regulatory uncertainty, reliance on licensors and third-party manufacturers, COVID-19-related trial or supply disruption, competition, and dependence on future financing. The filing highlighted that outstanding shares plus shares reserved for options and warrants were nearing the 250 million authorized-share limit. As of April 30, 2021, 215.5 million shares were outstanding and 34.0 million were reserved.
- Management stated disclosure controls were effective as of March 31, 2021. A prior material weakness in controls over clinical-trial cost accruals was reported as remediated as of December 31, 2020.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for ZIOPHARM Oncology, Inc., not a registrant named Alaunos Therapeutics, Inc.
- Track actual cash burn against the stated runway into Q2 2022 and assess financing needs, dilution, and authorized-share capacity.
- Review execution and costs of the Controlled IL-12 wind-down and the shift of resources to Sleeping Beauty TCR, including any further restructuring or vendor charges.
- Monitor enrollment, safety and clinical progress in the company-sponsored TCR trial and partner- or NCI-run studies, including the NCI enrollment suspension.
- Assess the effect of leadership transitions, license and collaboration obligations, and third-party manufacturing or supply dependencies.